Efforts to revitalise the five brands that make up the Lanvin Group are under way and should pay off in the medium term. However, at this stage of development (critical mass not yet achieved for some brands, negative profitability and cash burn) and in a consumer environment that does not yet point to a rebound, we prefer to remain cautious on the share. We are initiating coverage with a Neutral rating, with a target price of $ 1.80, based on a DCF valuation. - ...
Les efforts de redynamisation sont en cours pour les 5 marques qui constituent Lanvin Group et devraient porter leurs fruits à moyen terme. Toutefois, à ce stade de développement (taille critique encore non atteinte sur certaines marques, rentabilité négative et consommation de cash) et dans un environnement de consommation n’indiquant pas encore de rebond, nous préférons rester encore prudents sur le titre. Nous initions à Neutre, avec un OC à 1.8 $ résultant d’une valorisation par D...
3Q'24 vs. 3Q'23 Results Sales: € 151.7 M (-16.5% vs. -2.9% consensus); EBITDA: € 16.8 M (-43.1% vs. -29.5% consensus); Net Profit: € -7.9 M (vs. € 6.9 M consensus); 9M'24 vs. 9M'23 Results Sales: € 497.8 M (+5.8% vs. +11.1% consensus); EBITDA: € 57.7 M (-10.5% vs. -4.3% consensus); Net Profit: € 6.7 M (vs. € 22 M consensus);
Rdos. 3T'24 vs 3T'23: Ventas: 151,7 M euros (-16,5% vs -2,9% consenso); EBITDA: 16,8 M euros (-43,1% vs -29,5% consenso); BDI: -7,9 M euros (vs 6,9 M euros consenso). Rdos. 9meses'24 vs 9meses'23: Ventas: 497,8 M euros (+5,8% vs +11,1% consenso); EBITDA: 57,7 M euros (-10,5% vs -4,3% consenso); BDI: 6,7 M euros (vs 22 M euros consenso).
>Q3 2024: Revenues down 17% and EBITDA margin of 11.1% - Talgo yesterday evening reported Q3 2024 results well below expectations.Revenues came in at € 152m (the consensus at € 176m), down 17% on Q3 2023. Over 9M 2024, sales are still up 6%, with the acceleration of ongoing projects (DB, DSB). We believe that the sharp slowdown in Q3 is due to the failure to reach certain milestones on these two projects during the quarter.The EBITDA margin stood at 11.1% (c...
>T3 2024 : CA en recul de ~17% et marge d’EBITDA de 11.1% - Talgo a publié hier soir des résultats T3 2024 largement inférieurs aux attentes.Le chiffre d’affaires atteint 152 M€ (css à 176 M€), en recul de près de 17% vs T3 2023. Sur 9M, le CA est toujours en hausse de 6% avec l’accélération de l’exécution des projets en cours (DB, DSB). Le fort ralentissement du T3 est, selon nous, expliqué par la non-atteinte de certains milestones sur ces deux projets lors du ...
NEWS SUMMARY: CAIXABANK, ENDESA, GRIFOLS, POSSIBLE TAX CHANGES, TALGO. Russia shakes markets The threat of using nuclear weapons by Russia after Ukraine used its long-range missiles on Russian territory led to corrections in European stock markets that eased throughout the session after the Foreign Minister S. Lavrov stressed that Russia does not wish nor expect a nuclear war. Thus, in the STOXX 600, Real Estate and Pharma were the only sectors ending with gains vs. Banks and Automobiles that ...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CAIXABANK, GRIFOLS, IMPUESTOS ESPAÑA, TALGO. EUROPA: NOKIA. Rusia agita los mercados La amenaza de uso de armas nucleares por parte de Rusia después de que Ucrania utilizase sus misiles de largo alcance sobre territorio ruso deparó una sesión de caídas en Europa, que fueron moderándose a lo largo de la sesión después de que el ministro de exteriores ruso S. Lavrov remarcase que el país no desea ni espera una guerra nuclear. Así, dentro del STOXX 600...
NEWS SUMMARY: FERROVIAL, GRIFOLS, IBERDROLA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’24 results to be released over the coming days in Spain. US inflation continues to follow the script European stock markets ended with drops, although the US inflation data helped distance them from daily lows. In the STOXX 600 the best-performing sectors were Energy and Consumer Goo...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: FERROVIAL, GRIFOLS, IBERDROLA. EUROPA: ASML, DEUTSCHE TELEKOM, PROSUS, SIEMENS. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’24 que se publicarán en España y Europa en los próximos días. La inflación estadounidense sigue el camino esperado Las bolsas europeas terminaron con caídas, aunque el dato de i...
Enagas reported 9M24 results last week. Following this, we have changed our opinion on Enagas from negative to neutral. The Spanish utility sold its stake in Tallgrass in July 2024, reducing its indebtedness. Fitch Ratings and Standard & Poor's have upgraded Enagas to BBB+ and Moody's now has the issuer on a positive outlook (rating at Baa2). What restrains us from being positive on Enagas is the coming regulatory review and possibly further lower remuneration on Spanish gas pipelines. We also s...
A director at Iberdrola S.A. bought 10,000 shares at 13.740EUR and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
NEWS SUMMARY: IBERDROLA, ROVI, VISCOFAN. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’24 results to be released over the coming days in Spain. IBEX leading the way once again It was a negative session on both sides of the Atlantic, except for the IBEX, in another day with all eyes on results. In the Stoxx 600, most of the sectors (15/20) ended with losses, led by Basic Ma...
>Opinion Neutre et OC à 15.3 € maintenus - Les résultats du 9M 24 sont ressortis un peu au-dessus de nos attentes et de celles du consensus. Comme attendu, la stratégie de résilience du groupe lui permet de bénéficier, sur les trois premiers trimestres, de la progression des activités régulées grâce à la croissance de la base d’actifs et aux révisions tarifaires. Cela a permis de largement compenser une activité de génération bénéficiant certes d’un bon niveau d’hydro...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IBERDROLA, ROVI, VISCOFAN. EUROPA: DANONE, DEUTSCHE TELEKOM, KERING, SIEMENS. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’24 que se publicarán en España y Europa en los próximos días. El Ibex volvió a liderar Jornada negativa a ambos lados del Atlántico salvo para el Ibex en una nueva sesión descarg...
>Neutral recommendation and € 15.3 target price maintained - Earnings for the first nine months of 2024 came in slightly higher than we and the consensus had forecast. As expected, the group’s strategy to become more resilient allowed it to benefit over the first three quarters from an increase in regulated activities thanks to growth in the asset base and revised tariffs. This handily offset the generation business, which although it benefited from satisfactory hydro...
Last week, we organised an Expert Access event on multiple sclerosis (MS) with the participation of Dr Géraldine Androdias, a neurologist at Lyon University Hospital. Dr Androdias presented the key points of the ECTRIMS 2024 conference, as well as new trends in treating the illness. We note an unmet need in the primary progressive and secondary progressive forms, a real interest for the BTKi class with the greater penetration of the blood-brain barrier, and expectations for the anti-C...
Nous avons organisé la semaine dernière un Expert Access autour de la sclérose en plaques (SEP) avec la participation du Dr Géraldine Androdias, médecin neurologue au CHU de Lyon. Le Dr Androdias a présenté les points saillants du congrès de l’ECTRIMS 2024 ainsi que les nouvelles tendances dans la prise en charge de la maladie. Nous retenons un besoin insatisfait dans les formes progressives et secondairement progressives, un vrai intérêt de la classe des BTKi avec le passage accru de...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.